Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 2/20 | 0.46 |
| ▸ | ANPEP | P15144 | 2/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.40 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | RET | P07949 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CDK4 | P11802 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | CCND1 | P24385 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4116682 | 1.00 | PRCP (0.46) | PRCPANPEPHTR2AXIAPTRPM8 | |
| SCHEMBL4120258 | 1.00 | PRCP (0.46) | PRCPANPEPHTR2AXIAPTRPM8 | |
| SCHEMBL4117548 | 0.82 | SIGMAR1 (0.48) | ANPEP | |
| SCHEMBL4128510 | 0.82 | SIGMAR1 (0.48) | ANPEP | |
| SCHEMBL4117310 | 0.82 | SIGMAR1 (0.48) | ANPEP | |
| SCHEMBL4552272 | 0.81 | PRCP (0.49) | PRCPANPEPHTR2ATRPM8ALDH1A1 | |
| SCHEMBL4969263 | 0.81 | PRCP (0.49) | PRCPANPEPHTR2ATRPM8ALDH1A1 | |
| SCHEMBL14169872 | 0.81 | PRCP (0.44) | PRCPXIAPMEN1USP2ALDH1A1 | |
| SCHEMBL4415387 | 0.80 | SRD5A1 (0.40) | MTNR1BOPRM1 | |
| SCHEMBL4415385 | 0.80 | SRD5A1 (0.40) | MTNR1BOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8258302-B2 | Method for producing benzazepinone | API CORPORATION (JP) | 2012-09-04 | — | — | US | disclosed |
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API CORPORATION (JP) | 2009-07-02 | — | — | US | disclosed |
| EP-1985615-A1 | METHOD FOR PRODUCING BENZAZEPINONE | API Corporation (JP) | 2008-10-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090171090-A1 | METHOD FOR PRODUCING BENZAZEPINONE | NISCH, GABBR1, GABBR2 | PRCP 1094/4885ANPEP 709/4885HTR2A 428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.